Prolonged islet allograft survival in diabetic mice upon macrophage depletion by clodronate-loaded erythrocytes.

Early impairment of islet function and graft loss strongly limit the success of allogenic islet transplantation in insulin-dependent diabetes. Macrophages play a key role in this process thus the depletion of these cells may strongly affect islet survival. In this study, we have evaluated the effect of the depletion of macrophages in mouse allograft rejection using a new approach based on a single infusion of red blood cells loaded with the synthetic analogue of pyrophosphate clodronate. Graft survival was 19.4+/-0.89 and 20+/-2 days in the two control groups treated with physiological solution and unloaded erythrocytes, respectively; 25+/-1.9 days in the group treated with free-clodronate and 35+/-6 days in the erythrocytes-loaded group. Our results indicate clodronate selectively targeted to the macrophagic cells by a single administration of engineered erythrocytes can significantly prolong islet graft survival and open new therapeutic strategies in islet transplantation.

[1]  Jeffrey A. Johnson,et al.  Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. , 2007, Transplantation.

[2]  E. Bonifacio,et al.  Relevance of Hyperglycemia on the Timing of Functional Loss of Allogeneic Islet Transplants: Implication for Mouse Model , 2007, Transplantation.

[3]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[4]  S. Messinger,et al.  Quality of Life After Islet Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  O. Ohara,et al.  Vα14 NK T cell–triggered IFN-γ production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets , 2005, The Journal of experimental medicine.

[6]  A. Andriulli,et al.  Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients—A Pilot Uncontrolled Study , 2005, The American Journal of Gastroenterology.

[7]  T. Berney,et al.  Macrophage Depletion Prolongs Discordant but not Concordant Islet Xenograft Survival , 2005, Transplantation.

[8]  M. Magnani,et al.  Macrophage depletion induced by clodronate-loaded erythrocytes , 2005, Journal of drug targeting.

[9]  Gianluca Damonte,et al.  Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. , 2004, Blood cells, molecules & diseases.

[10]  P. de Vos,et al.  Macrophage depletion improves survival of porcine neonatal pancreatic cell clusters contained in alginate macrocapsules transplanted into rats , 2003, Xenotransplantation.

[11]  C. Ricordi,et al.  Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. , 2003, Diabetes.

[12]  M. Magnani,et al.  Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides , 2002, Gene Therapy.

[13]  U. Boggi,et al.  Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  M. Magnani,et al.  Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. , 2001, The Journal of antimicrobial chemotherapy.

[15]  L Bigi,et al.  Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.

[16]  A. De Flora,et al.  Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. , 1999, AIDS research and human retroviruses.

[17]  C. Ricordi,et al.  Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. , 1998, Diabetes.

[18]  M. Dallman,et al.  Cytokine gene expression in pancreatic islet grafts in the rat. , 1997, Transplantation.

[19]  A. De Flora,et al.  Targeting antiviral nucleotide analogues to macrophages , 1997, Journal of leukocyte biology.

[20]  M. Magnani,et al.  Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. , 1996, Biochimica et biophysica acta.

[21]  M. Magnani,et al.  Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Dunn,et al.  Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts , 1990, The Journal of experimental medicine.

[23]  P. Allavena,et al.  Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. , 2002, Diabetes.

[24]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .